Skip Navigation


NDT Advance Access originally published online on October 25, 2005
Nephrology Dialysis Transplantation 2006 21(2):370-377; doi:10.1093/ndt/gfi209
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/370    most recent
gfi209v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levin, A.
Right arrow Articles by Werb, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levin, A.
Right arrow Articles by Werb, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Original Articles: Clinical Nephrology

Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes

Adeera Levin, Ognjenka Djurdjev, John Duncan, Debbie Rosenbaum and Ron Werb

Division of Nephrology, University of British Columbia, Vancouver BC V6Z1Y8, Canada

Correspondence and offprint requests to: A. Levin, MD, FRCPC, Professor of Medicine, Division of Nephrology, University of British Columbia, 1081 Burrard Street, Rm 6010A, Vancouver BC Canada V6Z1Y8. Email: alevin{at}providencehealth.bc.ca

Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients.

This analysis evaluates the association of baseline haemoglobin levels on survival in CKD patients, who are followed by nephrologists, irrespective of glomerular filtration rate (GFR), prior to initiation of renal replacement therapy (RRT) and erythropoietin hormone replacement therapy.

Analysis of data from the provincial database (PROMIS, Patient Registration and Outcome Management Information System) in British Columbia, Canada, was undertaken. Records used for the analysis included all CKD patients at first registration: GFR <60 ml/min/1.73 m2, not yet on dialysis, starting from May 1998 to October 2002, and who had complete data (defined as age and gender, diabetic status, eGFR and Hgb levels).

The primary objective of this study was to determine the association of Hgb and survival controlling for eGFR at first registration value, age, gender and diabetic status. Multivariate Cox proportional hazards analysis with time to death as outcome variable was performed.

The cohort included 3028 patients: the mean age was 65 years, 28% were diabetic, and the mean eGFR in the cohort was 21 ml/min/1.73 m2. The cohort is representative of the BC CKD and dialysis population regarding ethnicity: 64% Caucasian, 32% Asian. Median follow-up was 27 months, 1 year survival was 0.92, 2 year survival was 0.85. Hgb at initial registration is a statistically independent predictor of survival (RR = 0.875 for every 10 g/l, 95% CI: 0.835–0.917, P = 0.0001), after adjusting for age, gender, diabetic status and baseline eGFR. Further analysis, controlling for RRT, demonstrated a similar association between Hgb and survival (RR = 0.853 for every 10 g/l, 95% CI: 0.799–0.910, P = 0.0001), after adjusting for above variables. Substantial variation in Hgb values exists at all GFR levels.

These findings underscore the importance of evaluating Hgb at all GFR levels, and the need to study the impact of modification of Hgb at different GFR levels on survival.

Keywords: anaemia; chronic kidney disease; independent effect; observational cohort study; survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
I. C. Macdougall, C. R.V. Tomson, M. Steenkamp, and D. Ansell
Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up
Nephrol. Dial. Transplant., November 23, 2009; (2009) gfp550v1.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
T. P. Moraes, R. Pecoits-Filho, S. C. Ribeiro, M. Rigo, M. M. Silva, P. S. Teixeira, D. D. Pasqual, R. Fuerbringer, and M. C. Riella
PERITONEAL DIALYSIS IN BRAZIL: TWENTY-FIVE YEARS OF EXPERIENCE IN A SINGLE CENTER
Perit. Dial. Int., September 1, 2009; 29(5): 492 - 498.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. Minutolo, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, D. Avino, S. Mascia, S. Laurino, V. Bertino, G. Conte, et al.
Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
L. De Nicola, G. Conte, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, G. Tirino, D. Avino, F. Catapano, and R. Minutolo
Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 938 - 946.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.